A randomized, double-blind, placebo controlled, multicenter, phase 3, pivotal study with an open-label extension period to evaluate the efficacy and safety of rozanolixizumab in adult participants with myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOG-AD) (MOG001)

Principal Investigator

Dr Jackie A Palace

Contact us

Email: ana.cavey@ouh.nhs.uk

IRAS number

1003956